Therefore, instead of modulating CXCR4 expression, anti-HIV modalities targeting an HIV gene or component should probably protect hematopoietic cells including T-lineage cells and CD34+ cells from CXCR4-tropic HIV infection (83). This evidence concerns the gene CD34 and HIV infectious disease.